SMA patients stick with Evrysdi for years, real-world study finds
WHY IT MATTERS
If you or your child has SMA and are considering Evrysdi, this real-world evidence shows that patients successfully stay on the treatment for years, suggesting it's a practical long-term option with good tolerability.
A study in Spain found that people with spinal muscular atrophy (SMA) who take Evrysdi, an oral medication, stick with the treatment long-term. All patients in the study continued taking the drug, with some staying on it for over three years. This shows the medication is well-tolerated and patients find it easy to keep using.
People with spinal muscular atrophy (SMA) show high long-term adherence to treatment with Evrysdi (risdiplam), with several patients remaining on the oral therapy after three years, according to a real-world study in Spain. The observational study, which involved adults and children with different SMA types, demonstrated that all patients adhered to treatment — a metric of […] The post SMA patients stick with Evrysdi for years, real-world study finds appeared first on SMA News Today .
ASK YOUR DOCTOR
If you have SMA and haven't started Evrysdi or are considering treatment options, ask your neurologist about this study's findings on long-term adherence and whether Evrysdi might be right for you.